A Neuropsychopharmacology Circumspectives article argues that cannabidiol has genuine therapeutic potential, especially in treatment-resistant pediatric epilepsy, but evidence for most other uses remains limited, heterogeneous, and not yet mature enough for broad clinical adoption. The authors also warn that poor retail product quality, inaccurate labeling, contaminants, hepatotoxicity risk, and drug interactions are major barriers to safe and effective real-world use.
from News Medical Medical Research News Feed https://ift.tt/NrRFIwv
0 Comments